Table 3—

Number of drugs supplied to male obstructive sleep apnoea(OSA) patients in the 5 yrs prior to diagnosis

Young adultsMiddle-aged adults
DrugsDifferencep-value#DrugsDifferencep-value#
Respiratory system (R)6.5±1.1 (3; 0–85)3.0±1.3 (0.4–5.6)0.0027.8±1.2 (4; 0–110)4.8±1.2 (2.3–7.2)<0.0001
Antibacterials for systemic use (J01)3.4±0.7 (2; 0–73)1.0±0.7 (-0.5–2.5)*0.064.4±0.5 (3; 0–31)2.1±0.5 (1.1–3.2)<0.0001
Cardiovascular system (C)3.4±1.4 (0; 0–140)3.0±1.5 (0.1–6.0)0.219±3.5 (1; 0–209)12.9±4.0 (5.1–21)<0.0001
Psycholeptics and psychoanaleptics (N05, N06)3.0±1.1 (0; 0–70)2.8±1.1 (0.7–5.0)0.043.9±1.1 (0; 0–85)2.9±1.1 (0.7–5.1)0.001
Analgesics (N02)2.5±0.8 (1; 0–92)1.4±0.9 (-0.3–3.1)0.125.2±0.9 (2; 0–51)2.7±0.9 (0.9–4.5)0.002
Anti-inflammatory and antirheumatic products (M01)0.8±0.1 (0; 0–6)0.22±0.10 (-0.05–0.5)0.22.6±0.4 (2; 0–25)1±0.5 (0.06–1.9)0.008
Peptic ulcer and gastro-oesophageal reflux disease (A02B)0.4±0.14 (0; 0–14)-0.5±0.5 (-1.5–0.5)0.834.1±1.0 (0; 0–63)3.2±0.9 (1.4–4.9)<0.0001
Drugs used in diabetes (A10)0.33±0.33 (0; 0–39)0.34±0.34 (-0.33–1.01)*0.63.7±1.5 (0; 0–115)3.2±1.4 (0.4–5.9)0.03
  • Data are presented as mean±sem (median; range) number of drugs supplied per patient during the 5 yrs prior to OSA diagnosis and as mean±sem (95% confidence interval) difference in prescription number over the 5 yrs. Differences between patients and controls were found in all pharmacological groups shown (a similar methodological approach was used to that in 10). Cardiovascular categories include: cardiac therapy and selective calcium channel blockers with direct cardiac effect (C01 and C08D); centrally and peripherally acting antiadrenergic agents (C02A and C02C); agents acting on arteriolar smooth muscle (C02D); thiazides, other low-ceiling diuretics, potassium-sparing agents and diuretics, and potassium-sparing agents in combination (C03A, C03B, C03D and C03E); high-ceiling diuretics (C03C); peripheral vasodilators (C04); vasoprotectives (C05); β-blocking agents (C07); selective calcium channel blockers with mainly vascular effects (C08C); plain and combination angiotensin-converting enzyme inhibitors (C09A and C09B); plain and combination angiotensin II antagonists (C09C and C09D); and cholesterol and triglyceride reducers (C10A). *: p<0.05; #: Wilcoxon test; : p<0.0001 versus middle-aged OSA patients (Mann–Whitney U-test).